JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer

  • 0Department of Surgery, The Royal Melbourne Hospital, Urology Department, University of Melbourne, Melbourne, Victoria, Australia.
Bju International +

|

September 30, 2025

|

September 30, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Prostate-specific membrane antigen (PSMA) PET/CT has a low diagnostic yield for staging intermediate-risk prostate cancer. More research is needed to determine its role in clinical decision-making for specific patient subgroups.

Area Of Science

  • Oncology
  • Radiology
  • Medical Imaging

Background

  • Prostate cancer (PCa) staging is crucial for treatment decisions.
  • The role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in intermediate-risk PCa requires clarification.
  • Current guidelines have uncertainties regarding PSMA PET/CT utility in this patient group.

Purpose Of The Study

  • To evaluate the diagnostic utility of PSMA PET/CT for primary staging in intermediate-risk prostate cancer.
  • To synthesize existing data on PSMA PET/CT performance in this specific PCa risk group.

Main Methods

  • Systematic literature search for studies on PSMA PET/CT in primary staging of intermediate-risk PCa (EAU/NCCN criteria, Gleason Score 7, ISUP GG 2-3).
  • Primary outcome: overall positive scans (lymph nodes or distant metastases).
  • Secondary analysis: diagnostic accuracy metrics including sensitivity, specificity, PPV, and NPV.

Main Results

  • Pooled analysis of 13 studies showed a 9% positivity rate for PSMA PET/CT in intermediate-risk PCa.
  • Positivity rates varied: 2.2–21.4% for ISUP GG 2 and 13.6–33.3% for ISUP GG 3.
  • Overall sensitivity for nodal and metastatic disease was low (33%), with limitations including small sample sizes and retrospective designs.

Conclusions

  • PSMA PET/CT demonstrates a low yield for primary staging in intermediate-risk prostate cancer.
  • Limited data exist to guide its use in favorable versus unfavorable subgroups.
  • Robust, prospective studies are necessary to define its clinical role and inform future guidelines.

Keywords:

Related Concept Videos

Positron Emission Tomography 01:29

6.9K

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy 01:25

503

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

Radioactive Tracer: PET involves using biologically active molecules labeled with radioactive isotopes, known as tracers or radiotracers. The...

Radiological Investigation III: Pulmonary Angiogram and PET Scan 01:13

405

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...